Medical treatment for gastro-entero-pancreatic neuroendocrine tumours

doi:10.4251/wjgo.v8.i4.389

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8820)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

671

WORD

377

HTML

4785

Figures (1-1)

243

Tables (1-2)

257

Sum=6333

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

999

Download

1488

Sum=2487

Apr 15, 2016 (publication date) through Jan 4, 2025

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Apr 15, 2016; 8(4): 389-401
Published online Apr 15, 2016. doi: 10.4251/wjgo.v8.i4.389

Table 2 Ongoing phase II trials in gastro-entero-pancreatic neuroendocrine tumours

ClinicalTrials.gov Identifier	Investigated drug	Target	Type of enrolled pts
NCT01841736	Pazopanib	VEGFR PDGFR FGFR c-kit	Progressive carcinoid tumours
NCT02399215	Nintedanib	VEGFR FGFR PDGFR	Carcinoid tumour Metastatic carcinoid tumour Neuroendocrine neoplasm
NCT01994213	Famitinib	c-kit PDGFR VEGFR Flt	Gastroenteropancreatic neuroendocrine tumour
NCT01121939	Bevacizumab plus pertuzumab plus sandostatin LAR	VEGF HER2	Advanced neuroendocrine cancers
NCT02259725	Regorafenib	c-RAF BRAF VEGFR PDGFRa FGFR-1 c-kit RET Flt-3	Gastrinoma Glucagonoma Insulinoma Metastatic gastrointestinal carcinoid tumour Pancreatic polypeptide tumour Pulmonary carcinoid tumour Recurrent gastrointestinal carcinoid tumour Recurrent Islet cell carcinoma Somatostatinoma
NCT01784861	X-82 plus everolimus	mTOR	Pancreatic neuroendocrine tumours
NCT01508104	BEZ235 plus everolimus	PI3K	Advanced cancers of different types
NCT00781911	Cixutumumab	IGF-1R	Neuroendocrine tumours

VEGFR: Vascular endothelial growth factor receptor; PDGFR: Platelet derived growth factor receptor; FGFR: Fibroblast growth factor receptor; mTOR: Mammalian target of rapamycin; PI3K: Phosphoinositide 3-kinase; IGF-1R: Insulin-like growth factor-1 receptor; pts: Patients.

Citation: Berardi R, Morgese F, Torniai M, Savini A, Partelli S, Rinaldi S, Caramanti M, Ferrini C, Falconi M, Cascinu S. Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World J Gastrointest Oncol 2016; 8(4): 389-401
URL: https://www.wjgnet.com/1948-5204/full/v8/i4/389.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i4.389